Core Viewpoint - Apogee Therapeutics, Inc. has successfully closed a public offering of 5,750,000 shares at a price of $70.00 per share, raising approximately $403 million in gross proceeds before expenses [1]. Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology markets, targeting conditions such as Atopic Dermatitis, asthma, Eosinophilic Esophagitis, and Chronic Obstructive Pulmonary Disease [5]. - The company's lead program, Zumilokibart (APG777), is aimed at treating Atopic Dermatitis, which is identified as a significant and under-penetrated market [5]. - Apogee's antibody programs are designed to enhance efficacy and dosing by utilizing advanced antibody engineering to optimize therapeutic properties [5]. Offering Details - The public offering included the full exercise of underwriters' option to purchase an additional 750,000 shares, indicating strong demand [1]. - Jefferies, TD Cowen, Stifel, and Guggenheim Securities served as joint book-running managers for the offering, with Wedbush PacGrow and BTIG acting as lead managers [2].

Group 1 - Apogee Therapeutics, Inc. has announced a public offering of 5,000,000 shares of common stock at a price of $70.00 per share, aiming for gross proceeds of approximately $350 million before expenses [1] - The offering is expected to close on March 26, 2026, pending customary closing conditions [1] - Underwriters have an option to purchase an additional 750,000 shares within 30 days at the public offering price [1] Group 2 - Jefferies, TD Cowen, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering, with Wedbush PacGrow and BTIG as lead managers [2] - An automatically effective shelf registration statement was filed with the SEC on August 12, 2024, and the offering is being made through a written prospectus [3] Group 3 - Apogee Therapeutics is focused on developing novel biologics for inflammatory and immunology markets, targeting conditions such as Atopic Dermatitis, asthma, Eosinophilic Esophagitis, and Chronic Obstructive Pulmonary Disease [5] - The company's lead program, Zumilokibart (APG777), is being developed for Atopic Dermatitis, which is a significant and under-penetrated market [5] - Apogee aims to achieve best-in-class efficacy and dosing through its antibody programs, which are designed to overcome limitations of existing therapies [5]

Core Viewpoint - Apogee Therapeutics, Inc. has initiated a public offering of $300 million in common stock to support its clinical-stage biotechnology efforts in the inflammatory and immunology markets [1] Group 1: Offering Details - The company plans to grant underwriters a 30-day option to purchase an additional $45 million in shares at the public offering price [1] - The offering is subject to market conditions, and there is no guarantee regarding its completion or terms [1] Group 2: Use of Proceeds - Net proceeds from the offering will be used for preclinical studies, clinical trials, manufacturing, and commercial readiness activities related to its antibody programs [2] - Additional funds will support research and development, capital expenditures, working capital, and general corporate purposes [2] Group 3: Management and Registration - Jefferies, TD Cowen, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering [3] - An automatically effective shelf registration statement was filed with the SEC on August 12, 2024, and the offering will be conducted via a written prospectus [4] Group 4: Company Overview - Apogee Therapeutics focuses on developing novel biologics for treating conditions such as Atopic Dermatitis, asthma, Eosinophilic Esophagitis, and Chronic Obstructive Pulmonary Disease [6] - The company's lead program, Zumilokibart (APG777), targets Atopic Dermatitis, aiming for best-in-class efficacy and dosing through advanced antibody engineering [6]

Core Insights - Apogee Therapeutics is advancing its clinical pipeline, particularly zumilokibart (APG777), with significant milestones expected in atopic dermatitis (AD) and other indications [1][2][3] Pipeline Progress - APEX Phase 2 Part A 52-week data for zumilokibart is expected this month, while Part B 16-week data is anticipated in Q2 2026 [1][3] - Phase 3 trial initiation for zumilokibart in AD is targeted for the second half of 2026 [1][3] - Positive interim results from the Phase 1b trial in asthma support the potential for zumilokibart in multiple indications, with further details to be shared later this year [1][3] Financial Position - As of December 31, 2025, the company reported a strong cash position of $902.9 million, up from $731.1 million in 2024, providing a runway into the second half of 2028 [7] - Research and development (R&D) expenses increased to $214.7 million in 2025 from $167.9 million in 2024, driven by pipeline advancement and personnel-related costs [7] - General and administrative (G&A) expenses rose to $70.9 million in 2025 from $49.0 million in 2024, reflecting increased headcount and equity-based compensation [7] Market Strategy - The company aims to position zumilokibart as a "pipeline-in-a-product," with plans to expand its indications to asthma and eosinophilic esophagitis (EoE) [2][3] - A head-to-head trial of APG279 (zumilokibart + APG990) against DUPIXENT is ongoing, with interim data expected in the second half of 2026 [1][3]

Company Overview - Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing novel biologics for inflammatory and immune (I&I) markets, including treatments for Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD) [3] - The company's lead program, Zumilokibart (APG777), is being developed primarily for AD, which is identified as the largest and least penetrated market within I&I [3] - Apogee aims to achieve best-in-class efficacy and dosing through its antibody programs, which target established mechanisms of action and utilize advanced antibody engineering [3] Upcoming Events - Management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 9:10 a.m. E.T. [1] - The company will also attend the UBS Biotech Summit Miami on March 9, 2026, and the Jefferies Biotech on the Beach Summit on March 10, 2026 [1] Investor Relations - For investor inquiries, Noel Kurdi serves as the VP of Investor Relations at Apogee Therapeutics [4] - Media inquiries can be directed to Dan Budwick at 1AB [4]

Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immune (I&I) markets, including treatments for Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD) [2] - The company's lead program, Zumilokibart (APG777), is primarily aimed at treating AD, which is identified as the largest and least penetrated market within I&I [2] - Apogee's antibody programs are designed to enhance efficacy and dosing by targeting established mechanisms of action and utilizing advanced antibody engineering to improve properties such as half-life [2] Upcoming Events - Management of Apogee Therapeutics will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 2:00 p.m. E.T. [1] - A live and archived webcast of the event will be accessible on the company's website under the Investors section [1]

Title text 2 Zumilokibart (APG777) Asthma Phase 1b Interim Results January 6, 2026 Disclaimers and Forward-looking Statements This presentation contains certain "forward-looking statements" within the meaning of applicable securities laws. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements about the potential for zumilokibart (APG777) in asthma; Apogee's plans for its current and future product candidates and programs; ...